Clinical trial
Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients…
NCT00322296 · Fox Chase Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00322296 |
|---|---|
| Title | Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients With Parapsoriasis |
| Official title | A Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients With Parapsoriasis: a Topical Chemoprevention Strategy for Cutaneous T-cell Lymphoma. |
| Lead sponsor | Fox Chase Cancer Center, Other |
| Collaborators | Ligand Pharmaceuticals Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Parapsoriasis |
| Intervention type | Drug |
| Interventions | Bexarotene 1% gel |
| Enrollment | 8 |
| Start date | Apr 1, 2001 |
| Primary completion | Jul 1, 2004 |
| Completion | Aug 1, 2004 |
| First posted | May 5, 2006 |
| Last update posted | Apr 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: